NCT03574753View on ClinicalTrials.gov

Lung-MAP S1400K: c-MET Positive

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 16, 2018

Primary Completion Date

December 21, 2019

Study Completion Date

July 30, 2021

Conditions
Recurrent Squamous Cell Lung CarcinomaStage IV Squamous Cell Lung Carcinoma AJCC V7
Interventions
DRUG

ABBV-399

ABBV-399 (Process II), 2.7 mg/kg IV over 30 ± 10 minutes, Day 1, Every 21 days

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

SWOG Cancer Research Network

NETWORK

NCT03574753 - Lung-MAP S1400K: c-MET Positive | Biotech Hunter | Biotech Hunter